Cisplatin, Mitomycin C, Vindesine, and G-CSF Combination Regimen

This is a combination chemotherapy regimen with G-CSF support used in the treatment of non-small-cell lung cancer (NSCLC). The search results indicate that this combination, particularly the MVP regimen (mitomycin C, vindesine, and cisplatin) with G-CSF support, has been studied to potentially shorten the interval between treatment courses. The MVP regimen without G-CSF typically follows a 28-day cycle, with cisplatin 80 mg/m² administered intravenously on day 1, vindesine 3 mg/m² intravenously on days 1 and 8, and mitomycin C 8 mg/m² intravenously on day 1. The addition of G-CSF appears to be investigated as a means to reduce the interval between treatment courses, potentially improving treatment efficacy. ## Components of the Regimen **Cisplatin**: An alkylating agent that works by cross-linking DNA strands, preventing DNA replication and cell division. It's used to treat various forms of cancer including sarcomas, carcinomas, lymphomas, and germ cell tumors. **Granulocyte Colony-Stimulating Factor (G-CSF)**: A growth factor that stimulates the bone marrow to produce granulocytes and stem cells. In cancer treatment, it's used to reduce the incidence of infection in patients receiving myelosuppressive chemotherapy by accelerating neutrophil recovery. **Mitomycin C**: An antitumor antibiotic that acts as an alkylating agent, cross-linking DNA and inhibiting DNA synthesis. **Vindesine**: A vinca alkaloid that binds to tubulin, inhibiting microtubule formation and mitosis. ## Efficacy and Toxicity The MVP regimen (without explicitly mentioning G-CSF) has shown activity in advanced NSCLC with an overall response rate of 52% in one study. The median duration of response was 4.2 months, and the median survival was 10.6 months. The major toxicity of the MVP regimen is myelosuppression, with grade 3 or 4 leukopenia and thrombocytopenia occurring in 85% and 33% of patients, respectively. This significant myelosuppression is likely the rationale for investigating the addition of G-CSF to the regimen, as G-CSF can help manage neutropenia and potentially allow for shorter intervals between treatment courses. The addition of G-CSF to chemotherapy regimens like MVP is a strategy to reduce treatment-related neutropenia and potentially improve treatment outcomes by maintaining dose intensity.

Other names

MVP + G-CSF regimenMVP regimen with G-CSF support